Somnomed Limited ( (AU:SOM) ) has issued an announcement.
SomnoMed Limited, a leader in oral appliance treatment solutions for sleep-related breathing disorders, has assessed the potential impact of new reciprocal tariffs announced by the USA on its operations. With the Philippines as its primary manufacturing location, the company plans to absorb the immediate costs of these tariffs to ensure uninterrupted patient care. SomnoMed maintains its FY25 revenue guidance of approximately $105 million and an EBITDA of between $7 million to $9 million, demonstrating its commitment to stakeholders despite the evolving tariff situation.
More about Somnomed Limited
SomnoMed Limited is a public company specializing in treatment solutions for sleep-related breathing disorders such as obstructive sleep apnea, snoring, and bruxism. The company is known for its clinically proven oral appliance therapy, SomnoDent, which serves over 970,000 patients across more than 20 countries. SomnoMed emphasizes continuous innovation and adherence to medical manufacturing standards, supported by extensive clinical research.
YTD Price Performance: 133.33%
Average Trading Volume: 1,803
Technical Sentiment Signal: Sell
Current Market Cap: $68.84M
For detailed information about SOM stock, go to TipRanks’ Stock Analysis page.